LETTERS TO THE EDITOR

Individualised pulse oximetry limits in neonatal intensive care

EDITOR,—Gupta et al have successfully demonstrated that they were unable to accurately predict PaO2 from saturation monitoring even after standardising from a previous measurement. The rest of the conclusions presented in their discussion are however based upon interpretation of other research findings which is not further supported by their own study.

They correctly point out that the poor relation between SpO2 and PaO2 is related to differing proportions of fetal haemoglobin, PCO2, and acid–base balance. This begs a question, which their discussion fails to address, on whether the PaO2 or the SpO2 is the most useful index of oxygenation. It is certainly the case that normal in utero PO2 is within a range which they would describe as “hypoxic”. On the other hand, in the presence of 100% fetal haemoglobin, a saturations monitor should, in these circumstances, correctly indicate adequate saturation.

The authors also remark that transcutaneous oxygen monitoring is “a better way of non-invasively assessing PaO2”. They provide no evidence for this remark. It is certainly a common experience to find a saturation monitor alarming high when a transcutaneous oxygen monitor is apparently recording a normal pulmonary arterial oxygenation. The authors also remark that transcutaneous monitoring and this is a better way of continuously monitoring PaO2, than trying to extrapolate from the SpO2 signal. The ease with which pulse oximetry can be applied has led to the virtual abandonment of transcutaneous monitoring by many units. There are technical difficulties with transcutaneous monitoring as pointed out by Dr Clifford, but these can be overcome if the staff caring for the babies are familiar with the technique and use it on a routine basis. The anecdotal experiences of those units that continue to use transcutaneous monitoring as part of their clinical routine is that it remains an extremely useful technique.

The purpose of maintaining adequate arterial oxygenation is to provide oxygen to meet the metabolic demands of the baby, prevent pulmonary hypertension, and avoid oxygen toxicity. We do have a satisfactory method of defining what constitutes adequate oxygenation during intensive care at present and it is necessary to take into account other variables, such as haemoglobin concentration or tissue perfusion, which also determine oxygen delivery when we assess our patients.

ROLLO CLIFFORD
Consultant Paediatrician, Dorset County Hospital, Wimborne Avenue, Dorchester, Dorset DT1 2YJ, UK


Dr Yoxall and Dr Shaw respond:

Dr Clifford has raised the important question of whether PaO2 or SpO2 is the best index of arterial oxygenation. The answer to this question is, of course, unknown and the aim of our study was not to attempt to provide an answer. Most of the work defining hypoxia and harmful hyperoxia in neonates was performed in the era prior to pulse oximetry and therefore defines these situations in terms of partial pressure rather than oxyhaemoglobin saturation. The guidelines for good practice in the management of neonatal respiratory distress syndrome published by BAPM and RCP state that arterial blood sampling is the “gold standard” for assessing arterial oxygenation. In the absence of evidence to the contrary, we would agree with this.

Pulse oximetry is widely used during neonatal intensive care. Our study has shown that it is not possible to accurately predict PaO2 from SpO2 even after standardising from a previous measurement. The information provided by measurements of PaO2 and SpO2 is different and should not be interpreted as interchangeable. As SpO2 monitoring is non-invasive, continuous, and has a rapid response time, it useful for monitoring trends and particularly in detecting episodes of sudden desaturation.

Monitoring of PaO2 is possible using transcutaneous monitoring and this is a better way of continuously monitoring PaO2 than trying to extrapolate from the SpO2 signal. The ease with which pulse oximetry can be applied has led to the virtual abandonment of transcutaneous monitoring by many units. There are technical difficulties with transcutaneous monitoring as pointed out by Dr Clifford, but these can be overcome if the staff caring for the babies are familiar with the technique and use it on a routine basis. The anecdotal experiences of those units that continue to use transcutaneous monitoring as part of their clinical routine is that it remains an extremely useful technique.

The purpose of maintaining adequate arterial oxygenation is to provide oxygen to meet the metabolic demands of the baby, prevent pulmonary hypertension, and avoid oxygen toxicity. We do have a satisfactory method of defining what constitutes adequate oxygenation during intensive care at present and it is necessary to take into account other variables, such as haemoglobin concentration or tissue perfusion, which also determine oxygen delivery when we assess our patients.

ROLLO CLIFFORD
Consultant Paediatrician, Dorset County Hospital, Wimborne Avenue, Dorchester, Dorset DT1 2YJ, UK


Dr Slack and Dr Schapira respond:

We thank Dr Slack for his comments about our report. He is quite correct that neither we nor any of those authors who have previously described these events have provided any evidence that it is either the pertussis component of the diphtheria/tetanus/whole cell pertussis vaccine or its endotoxin content that is responsible for these reactions. That is why we described it as “the presumptive cause”.

It is possible that any of the vaccine components or adjuvants are responsible. It may simply be a response to a pain, although this seems unlikely. However, given the evidence of reduced local and systemic reactions with acellular pertussis vaccines in term infants compared with the UK whole cell vaccine, it seems plausible that the pertussis component may be involved.

He is partially correct in stating that the way to answer this would be to conduct a three way randomised trial between placebo, acellular (DTaP), and whole cell pertussis (DTP) vaccines. In fact, it would require multiple randomisations between Hib, DT, DTaP, one, two, three, and five component DTaP vaccines, and placebo. Even if the use of a placebo were ethically acceptable, which we believe it would not be the case, the low incidence of these events would make the number of infants required for such a study impossible large.

We are, however, conducting a multicentre study to determine the incidence of apnoeas following immunisation using a three component acellular vaccine.

Finally, we do not accept that we have joined the ranks of those who have shaken confidence in the vaccination programme.


Dr Slack and Dr Schapira are correct in drawing attention to a problem that is recognised and documented but not fully addressed or understood. Their suggestion that further studies are required to determine the optimum timing of immunisation for extremely preterm infants is sound (even though the adequate immunological response of these babies to vaccinations is well documented).

However they state that the presumed cause of the apnoeas is the pertussis component, with neither reference nor explanation of why they think this is the case. As the four antigens are given simultaneously it is not possible to identify the culprit. The American studies quoted1 could not identify whether one or a combination of antigens was the cause or indeed whether one of the several substances contained within vaccines contributed to the reaction. Indeed Sanchez et al merely postulate that pertussis is the most likely reason because it has been reported in the past to provoke more local and systemic reactions, although the incidence of associated reactions in their cohort was low.2 Botham et al claim that pertussis endotoxin acting centrally may stimulate apnoeas although there is no evidence for this. To make the determination of the nature of controlled trial of whole cell pertussis, acellular pertussis, and placebo would be required. Plainly this is not an ethical or practical option. Hence it would seem sensible to follow the suggested advice of monitoring these infants for 48 hours, especially in very low birth weight infants and those with chronic lung disease. The effects of implementing acellular pertussis vaccine will be awaited with interest.

In view of recent and not so recent media hysteria of unconfirmed (and indeed discounted) claims of the adverse effects of vaccines, we should not be fuelling this matter by making suppositions which cannot yet be supported by the scientific evidence.

D J STALKER
Specialist Registrar, Bristol Royal Hospital for Sick Children, St Michael’s Hill, Bristol BS2 8BJ, UK


The question is not whether preterm infants should be immunised against pertussis but when and with what vaccine.


Randomised controlled trial of cisapride in preterm infants

EDITOR.—I read with great interest the study by McClure et al reporting delayed gastric emptying and a non-significant increase in whole gut transit time in premature infants treated with cisapride.1 In contrast, placebo controlled studies evaluating cisapride in preterm infants have reported improvement in symptoms of gastro-oesophageal reflux disease or improvement in oesophageal pH results and/or manometry.2–4 As acknowledged by the authors, other studies in premature infants have reported a reduction in gastric residue and improved feed tolerance. In addition, we have reported a reduction in gastro-oesophageal reflux in premature infants.5

In this latest trial the authors chose hydroxypropylmethyl cellulose as a placebo, given at the “same volume” as cisapride; however, the actual quantity administered is not clear. Cellulose derivatives are commonly employed as laxatives, where it is proposed that they act by absorbing water, so softening the faeces and increasing stool volume. This in turn stimulates faecal propulsion.6 Clearly, depending on the dose of hydroxypropylmethyl cellulose used, the choice of this compound as a placebo is nonsensical as there could be a marked impact on gastrointestinal transit time. From the publication it is also not clear why gastrointestinal motility was measured after three days dosing; it is likely that any cathartic effect from a laxative would be less marked after more prolonged treatment time.

The manufacturer had recommended against the use of cisapride in premature infants because of concern that the metabolic pathway of cisapride may not be fully developed. However, in most European countries and the United States, cisapride is commonly used in premature (gestational age > 34 weeks) infants, and, despite this widespread use, the incidence of clinically important cardiovascular effects is very low. Such events are often associated with high doses (> 0.8 mg/kg/day) or concomitant administration of drugs known to inhibit cytochrome P450 that, like cisapride, are known to prolong the QT interval.

In my opinion, in view of the clinical experience with cisapride in severe gastro-oesophageal reflux disease and feed intolerance in premature infants, and the few clinically relevant cardiovascular events, treatment with cisapride with appropriate monitoring (electrocardiogram before and after two or three days of treatment) should not be withheld from these infants if clinically indicated.

YVAN VANDENPLAS
Academic Children’s Hospital Free University of Brussels Laarbeeklaan 101 1090 Brussels, Belgium


Dr McClure responds:

We agree, and indeed stated in our own paper1 that cisapride has been shown in children to improve symptoms of gastro-oesophageal reflux disease and to hasten both gastric emptying and gastrointestinal transit time. We believe that it is dangerous to assume that the immature gut of the preterm infant will react in the same manner. We further believe that our study has the strongest methodology of any previous cisapride treatment, not whole gastrointestinal transit time. We believe that it is dangerous to assume that the immature gut of the preterm infant will react in the same manner. We further believe that our study has the strongest methodology of any previous cisapride treatment, not whole gastrointestinal transit time.

The pharmacokinetics of cisapride in the preterm infant are unclear. A period of three days dosing before measurement of gastrointestinal motility was considered necessary to allow both time for acquisition of a steady serum cisapride level and adequate elimination of any previous cisapride treatment.


The use of cisapride in neonates

EDITOR.—In response to the annotation of Markiewicz and Vandelen,1 which give the indications for the use of cisapride in neonates, I performed a Medline search using the search terms “cisapride” and “infant, neonate” in which they referenced 14 studies. None of these studies were referenced in their annotation.1 Surely in these days of evidence based medicine, direct examination of the evidence available is mandatory.

The results of the search found in my study show that cisapride is only effective in: treating ileus after abdominal surgery; reducing the number of gastric residuals in nasogastrically fed preterm infants; and decreasing the incidence of regurgitation in preterm infants.3 Specifically cisapride was not effective in reducing the time taken to achieve full enteral feeds in preterm infants,4 and may delay gastric emptying in preterm infants.5

Furthemore it could be argued that gastro-oesophageal reflux is a normal pathological state in neonates, and only if it leads to complications (secondary respiratory disease, oesophaegitis) does it require treatment. No randomised controlled trial of cisapride versus placebo in neonates has been published that looks at these clinically relevant outcomes.

I would therefore argue that, given the side effect profile, the only indications for cisapride in neonates are treating obstructive ileus and, possibly, treatment of regurgitation leading to complications. At present there is no evidence that it is effective for use in neonates in any other circumstance.

MARK W DAVIES
Perinatal Research Centre, University of Queensland Royal Women’s Hospital, Brisbane, Australia 4029

1 Markiewicz M, Vandelen Y. Should cisapride have been “blacklisted”? Arch Dis Child Fetal Neonatal Ed 2000;82:169–70.


Mechanism of blood pressure increase induced by dopamine in hypotensive preterm neonates

EDITOR.—The paper of Zhang et al1 on the effects of dopamine relies on the assumption that left ventricular output (LVO) is a measure of systemic blood flow (SBF). This is not true in the presence of any shunt through the ductus arteriosus where LVO becomes the sum of SBF and volume of blood shunting back into the lungs through the duct, and so overestimates SBF. While Zhang et al1 define ducts in their study babies as insignificant, we would question the validity of the criteria used to make this definition. We have never seen shunting only in diastole, chamber enlargement is an inconsistent sign of ductal shunting and develops after day one, and shunt velocity has little relation to shunt size during week one. In fact, the left to right velocity often increases as the duct constricts and the shunt diminishes in size. Biventricular shunting is also usually predominantly left to right.

There is much in the data presented by Zhang et al1 to suggest that these ducts were highly significant; firstly, they select a population at high risk for a significant duct,
and secondly they measured a mean diameter of 2.9 mm. We showed that this measure is the most accurate predictor of early haemodynamic significance and that preterm ducts over 2 mm in diameter, with very few exceptions, have a haemodynamic impact.1 In this haemodynamic milieu, LVO is actually a measure of pulmonary blood flow, and right ventricular output becomes the better measure of SBF,2 but even this can be confounded by the common finding of left to right atrial shunting.3 That this haemodynamic impact is often present from the very early postnatal period is emphasised in fig 1 which is of a 5 hour old infant of 26 weeks gestation, in whom we measured an LVO of 350 ml/min per kg but a right ventricular output (RVO) of 90 ml/min per kg. This baby had an unrestricted duct (2.6 mm) with a low velocity (0.7 m/s) but high volume left to right shunt. In other words LVO was overestimating SBF by a factor of over 300%. This is not an unusual finding.1

This means that the changes in LVO in response to dopamine documented by Zhang et al may have occurred in the systemic circulation but, equally, could have occurred in the pulmonary circulation. The same uncertainty applies to changes in calculated vascular resistance. In other words, LVO may have increased or decreased solely because dopamine has changed the volume of the ductal shunt back into the lungs.

Early preterm ductal shunting should not be assumed to be inconsequential, and interpretation of early postnatal measures of either right or left ventricular output in preterm infants should be approached with caution.

NICK EVANS
DAVID OSBORN
 MARTIN KLUCKOW
Department of Neonatal Medicine
King George V Hospital for Mothers and Babies
Royal Prince Alfred Hospitals
Missenden Road
Camperdown
NSW 2050, Australia
email: nicks@med.usyd.edu.au

Figure 1 Doppler measures taken from a 26 week infant at 5 hours of age. (A) High velocity flow (about 1.0 m/s) in the ascending aorta representing a left ventricular output of 350 ml/min per kg. (B) Low velocity flow (about 0.2 m/s) in the pulmonary artery representing a right ventricular output of 90 ml/min per kg. (C) Low velocity (about 0.7 m/s) high volume laminar left to right flow through an unoccluded duct.


Dr Zhang et al respond:

Dr Evans and his colleagues have raised two main issues about our paper.1 The first relates to the haemodynamic significance of shunting through the ductus in our subjects. We readily acknowledged that shunting was present and that the measured left ventricular output was therefore an approximation of systemic tissue blood flow. This was unavoidable, as most babies were studied on the first day after birth, when the ductus is proceeding to close.2 However, on the basis of clinical assessment as well as other data not presented—for example, average left ventricular shortening fraction was 29%—we considered that myocardial dysfunction rather than ductal shunting was the most likely cause of the systemic hypotension shown.

Our study was confined to a select subgroup of babies with hypotension who failed to respond to volume loading and were thus started on inotropes. In contrast, the studies cited by Evans and colleagues were performed in groups of infants who may or may not have received volume loading and/or inotropic treatment1 and in whom the level of myocardial function ranged from depressed to normal.3 Furthermore, most of our subjects were studied beyond the initial 24 hours after birth, whereas the studies cited1 were performed over the course of the first postnatal week. Given the substantial physiological changes in the cardiovascular system,4 findings obtained in the middle or end of the initial week may not necessarily be applicable to the first day after birth.

Evans and colleagues state that “left ventricular output may have increased or decreased solely because dopamine changed the volume of the ductal shunt back to the lungs”. The physiological changes we observed suggest that this was unlikely and that dopamine exerted a vasoactive effect within the systemic circulation. Thus the premise that the increase in left ventricular output was related only to greater left to right ductal shunting is not in accord with the concomitant rise in systemic blood pressure induced by dopamine. The contention that falls in left ventricular output were merely due to a reduction in ductal shunting is inconsistent with the observed fall in superior mesenteric artery velocity and rise in superior mesenteric vascular resistance.

Letters, Book reviews

Retained umbilical artery catheter presenting as an umbilical abscess

EDITOR,—We report the delayed recognition of an umbilical artery catheter in an 18 month infant who presented with recurrent umbilical discharge.

A male infant was delivered by caesarean section which was complicated by a hypoglycaemic fit. Resuscitation included the attempted intubation of an umbilical venous catheter. The line was found to be arterial and thus removed. A second attempt also entered the umbilical artery, and, as the infant was now stable, no further attempt was made.

At 15 months, the infant presented with an umbilical abscess. This was investigated by drainage to exclude a urachal remnant. An ultrasound and abdominal radiograph showed a foreign body within the common iliac artery, and, using an infrabifemoral approach, part of an umbilical catheter was removed. The remnant was 10 cm in length.

During the neonatal period, the umbilicus is a useful route of vascular access. The umbilical artery can be used for blood pressure and gas tension measurement but all catheters should be removed early to avoid central infection.4 Other complications such as thrombosis and necrotising enterocolitis have been reported.4 Migration of umbilical vein catheters into the left atrium and pulmonary veins may occur.5 Retrieval of fractured umbilical catheters during the neonatal period has been reported.6

In this case, the retained catheter was not recognised until the infant presented late with recurrent umbilical infections and illustrates a need for a list of differential diagnoses. The history also re-emphasises that it is essential to check central lines for completeness on removal.

PETER TEMESVÁRI
Department of Pediatrics
University Teaching Hospital
Kecskemét, Hungary
email: temetespe@hotmail.com

References


Precordial pain relief

EDITOR,—The study of Jain and Rutter1 indicates that, after an hour of application, topical amethocaine gel exerts a demonstrable anaesthetic effect 54.8% of the time, indicating low potential for practical use. In the authors’ own words “a successful . . . anaesthetic should be quick acting, effective and safe . . .”. It is therefore disappointing to note that in the discussion no mention was made of oral sucrose as an analgesic agent for use in neonates undergoing painful procedures. This is despite a large body of evidence suggesting that it reduces the indicators of pain from various sources.2 Unfortunately there is a widespread reluctance of clinicians to use oral sucrose before performing painful procedures on neonates. We showed this in a recent study.3

Questionnaires were sent to the medical directors of the 18 neonatal units in New Zealand in order to determine the knowledge, attitudes, and practice with regard to commonly performed painful neonatal procedures such as blood taking or line placement. In the 15 replies, there was a high degree of awareness that the procedures caused pain (100%), that the physiological stress of pain was more hazardous than the risks of analgesia and anaesthesia (67%), and that oral sucrose was a safe and effective analgesic (87%) and yet only five units (33%) ever used any type of analgesia for these procedures and usually for less than 10% of the time. Only one unit (our own) used oral sucrose routinely. We find it to

Table 1 Results of survey of premedication practice for tracheal intubation in term and preterm neonates in Australia and the United Kingdom

<table>
<thead>
<tr>
<th></th>
<th>United Kingdom</th>
<th></th>
<th>Australia</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Term</td>
<td>Preterm</td>
<td>Term</td>
</tr>
<tr>
<td>Routine premedication (%)</td>
<td>22 (42)</td>
<td>18 (34)</td>
<td>15 (71)</td>
</tr>
<tr>
<td>Opiate</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BDZ</td>
<td>13</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Opiate + BDZ</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Opiate + muscle relaxant + atropine</td>
<td>6</td>
<td>11</td>
<td>9</td>
</tr>
<tr>
<td>BDZ + muscle relaxant + atropine</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Opiate</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BDZ</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

New South Wales Newborn and Paediatric Emergency Transport Service Wentworthville, NSW, Australia

STEPHEN HANCOCK
Department of Anaesthesia
Brook Prince Inflammatory
SIMON NEWELL
St James’s University Hospital Leeds

JOE BRIERLEY ANDREW BERRY
New South Wales Newborn and Paediatric Emergency


Perinatal cortical infarction with no obvious cause

EDITOR,—The study by Govaert et al of ultra-sonography in newborn infants with perinatal cortical infarction2 did not find a cause in 25% of cases. They also confirmed an association between stroke and pulmonary hypertension requiring assisted ventilation.3

We have previously observed on artificially ventilated newborn piglets with pneumothorax and pulmonary hypertension, showing cerebral arterial air microembolisations.4 In the case of artificial ventilation, which is often accompanied by pulmonary air leak syndrome (pulmonary interstitial emphysema, pneumomediastinum, pneumothorax), air can easily reach the cerebral vasculature, especially when there is persistent pulmonary hypertension and right to left intracardiac shunts.

In the light of our observations, as air microemboli could not be detected by ultrasound, I suspect that the perinatal cortical infarction may have been due to cerebral arterial air embolisation in some patients in the study by Govaert et al.

PÉTER TEMESVÁRI
Department of Pediatrics
University Teaching Hospital
Kecskemét, Hungary
email: temetespe@hotmail.com

References


Neonatal pain relief

EDITOR,—The study of Jain and Rutter1 indicates that, after an hour of application, topical amethocaine gel exerts a demonstrable anaesthetic effect 54.8% of the time, indicating low potential for practical use. In the authors’ own words “a successful . . . anaesthetic should be quick acting, effective and safe . . .”. It is therefore disappointing to note that in the discussion no mention was made of oral sucrose as an analgesic agent for use in neonates undergoing painful procedures. This is despite a large body of evidence suggesting that it reduces the indicators of pain from various sources.2 Unfortunately there is a widespread reluctance of clinicians to use oral sucrose before performing painful procedures on neonates. We showed this in a recent study.3

Questionnaires were sent to the medical directors of the 18 neonatal units in New Zealand in order to determine the knowledge, attitudes, and practice with regard to commonly performed painful neonatal procedures such as blood taking or line placement. In the 15 replies, there was a high degree of awareness that the procedures caused pain (100%), that the physiological stress of pain was more hazardous than the risks of analgesia and anaesthesia (67%), and that oral sucrose was a safe and effective analgesic (87%) and yet only five units (33%) ever used any type of analgesia for these procedures and usually for less than 10% of the time. Only one unit (our own) used oral sucrose routinely. We find it to

Arch Dis Child Fetal Neonatal Ed: first published as 10.1136/fn.83.1.F74 on 1 July, 2000. Downloaded from http://fn.bmj.com/ on October 28, 2023 by guest. Protected by copyright.
be highly effective, simple to use, and rapid in action. It is also exceedingly cheap.

We do not know why oral sucrose has failed to find much favour in neonatal units. Clearly neither lack of understanding of neonatal pain perception nor lack of knowledge about the analgesic properties of sucrose are significant factors. Perhaps there is an unrecognised prejudice against anything that is low tech, cheap, and not promoted by pharmaceutical companies.

PAUL HEATON
DAVID HERD
Child and Adolescent Community Centre
Taranaki Health
Private Bag 2016
New Plymouth 4620, New Zealand
email: paed.cacc@thcl.co.nz


BOOK REVIEWS


After fifty years, my only real memory of the paediatrics teaching of Professor A V Neale in Bristol is the benefit to children of sunlight and the aphorism “Preconceptual and Prenatal care is crippled by a large proportion of the disadvantaged population who further disadvantage themselves by their own actions”. Regrettably this text from the USA shows us that little has changed. Over these decades the rate of prematurity, intrauterine growth retardation (IUGR) and perinatal mortality has changed very little in spite of all our collective clinical efforts.

The male partner is hardly mentioned in this book so it seems that, to American eyes, the sole responsibility for producing healthy or unhealthy babies lies with the mother. All of us now know that many varied vaginal infections are associated with prematurity/prelabour rupture of the membranes and prematurity itself and that antibiotic treatment may have a reducing effect on these problems. Yet with a close reading of the chapter on vaginal infections, which is very well referenced, there appear to be no papers indicating that with all these infections possibly being sexually transmitted, no trials have included investigation and treatment of the male partner. For example, although Bacterial Vaginosis, Candida and Haemolytic Streptococcus are not usually recognised as sexually transmitted diseases (STD), all gynaecologists have witnessed cases where they have been the cause of recurrent vaginal infections.

Many chapters emphasise the adverse effects of alcohol, smoking, recreation drugs and poverty on the unborn fetus. I have always had a healthily sceptical interest in Jongbloet’s1 theory that alcohol consumption just before and at the time of conception may be responsible for a large number of chromosomal aberrations but this attractive theory is nowhere to be found in the book.

Meanwhile we are beset by new threats. A recent study,2 not mentioned in this book, shows ecstasy exposure being implicated in some congenital anomalies.

This is a well researched book with excellent references. Throughout, areas of research yet to be carried out are mentioned. For that reason alone it could serve as a good “ideas” source book for junior paediatricians and obstetricians to involve themselves in research projects which may one day help to reduce the continuing high incidence of potentially-damaged babies.

JOHN MCGARRY
Consultant Obstetrician and Gynaecologist in Independent Practice North Devon


Many will have experienced a feeling of being daunted when beginning a neonatal post as a doctor in training or as a neonatal nurse. The smaller the infant with which to be faced, the greater the concern over the ability to manage the infant appropriately. Levitt, Harvey and Cooke’s Practical Perinatal Care—The Baby Under 1000 Grams goes a long way to provide a very readable but authoritative book which will help prepare those in neonatal medical or nurse training to manage these infants. The book has a wide range of chapters from the practical aspects of how to put in an arterial line, perform a suprapubic aspiration of the bladder or drain a pneumothorax, to ventilation strategies, and ethical issues of the management of extremely low birth weight infants. The authors have rightly concentrated on the subgroup of neonatal patients who are less than 1000g at birth as these are undoubtedly the most challenging group, where there is the greatest mortality and morbidity, and where there is the possibility to improve the outcome with good care. Each chapter is relatively short but provides clear information from an evidence based perspective where available and is very well referenced.

There is an informative chapter on iatrogenic disease which reminds the reader as to the damage which may result from the procedures and treatment given, especially if care is not taken. All chapters conclude with a highlighted box of Practical Points and there are useful diagrams and a series of black and white photographs to aid the text, although occasionally these are too small to be of real value such as in the procedures chapter. Any senior house officer, specialist registrar, or neonatal nurse starting a neonatal post would be well advised to read this useful book which will sit nicely between the several general neonatal texts that are available and the more definitive works which will remain the mainstay of neonatal reference.

ANTHONY J B EMMERSON
Consultant Paediatrician St Mary’s Hospital Manchester